

**BREAST CANCER DEVELOPMENT IN RATS UNDER THE INFLUENCE OF
PLATELET FACTOR-4 (PF4) AND/ OR RAPAMYCIN**

by

ZAIHASSNI BINTI MAT YAMAN

**Thesis submitted in fulfillment of the requirement
for the degree of
Master of Science**

March 2016

ACKNOWLEDGMENT

First and foremost, I would like to thank the Almighty Allah for His countless blessing that has brought me this far. I would like to express my gratitude to my supervisor, Prof. Dr. Hasnan Jaafar, whose expertise, understanding, and patience added considerably to my graduate experience. Deepest gratitude also to my co-supervisor, Assoc. Prof. Dr. Azman Seeni Muhamad whose without his knowledge and assistance, this study would not have been successful.

This research project would not have been possible without the support of many people. Special thanks also to all my graduate friends, especially Wirda, Hilda, Rusidah, Damitri and Amira for their invaluable assistances, insightful comments, exchanges of knowledge, skills, and venting of frustration during my graduate program, which helped enrich the experiences. Not forgetting to all staffs of the Department of Pathology, Universiti Sains Malaysia (USM) especially Puan Umami Atikah, En. Rosli and Puan Jamaliah.

A special thanks to my beloved family, for their understanding and endless love through the duration of my studies. Words cannot be expressed how grateful I am to my parents and my siblings for all of the sacrifices that you've made on my behalf. Your prayer for me was what sustained me this far.

Last, but not least I recognized that this research would not have been possible without the financial assistance of USM research grant (RUI/ 1001/ PPSP/ 813035) and the My Brain15 Graduate Scholarship Fund (Ministry of Education).

TABLE OF CONTENTS

| | |
|---|------|
| ACKNOWLEDGMENT..... | ii |
| TABLE OF CONTENTS..... | iii |
| LIST OF PRESENTATION..... | ix |
| LIST OF TABLE..... | x |
| TABLE OF FIGURE..... | xi |
| LIST OF ABBREVIATIONS..... | xiv |
| ABSTRAK..... | xvii |
| ABSTRACT..... | xix |
| CHAPTER 1-INTRODUCTION | |
| 1.1 Background of the study..... | 1 |
| 1.2 Objectives of the study..... | 4 |
| 1.2.1 Specific objectives..... | 4 |
| CHAPTER 2- LITERATURE REVIEW | |
| 2.1 Breast Cancer..... | 5 |
| 2.1.1 The prevalence of breast cancer worldwide..... | 5 |
| 2.1.2 Breast cancer risks in Malaysia..... | 6 |
| 2.2 MNU induced breast cancer animal model..... | 9 |

| | | |
|-----|--|----|
| 2.3 | Anticancer properties of Platelet Factor-4 (PF4)..... | 11 |
| 2.4 | Rapamycin inhibits cancer cell growth..... | 13 |
| 2.5 | Regulation of Estrogen Receptor in Breast Cancer..... | 16 |
| 2.6 | Regulation of Progesterone receptor in Breast Cancer..... | 19 |
| 2.7 | Regulation of Peroxisome Proliferator Activation Receptory in Breast Cancer Cells..... | 20 |

CHAPTER 3- MATERIALS AND METHODS

| | | |
|---------|---|----|
| 3.1 | Study design..... | 24 |
| 3.2 | Materials..... | 26 |
| 3.2.1 | Materials for mammary tumour induction and interventions..... | 26 |
| 3.2.1.1 | Reagent preparation of MNU solution..... | 26 |
| 3.2.1.2 | Reagent preparation of Rapamycin solution..... | 26 |
| 3.2.1.3 | Reagent preparation of PF4 solution..... | 27 |
| 3.2.2 | Materials for Histology analysis..... | 27 |
| 3.2.2.1 | Reagent preparation of 10% Neutral Buffered Formalin (NBF) solution | 28 |
| 3.2.2.2 | Reagent preparation of Harris Hematoxylin working solution.... | 28 |
| 3.2.2.4 | Reagent preparation of 95% ethanol..... | 28 |
| 3.2.2.5 | Reagent preparation of 80% ethanol..... | 28 |

| | | |
|----------|---|----|
| 3.2.2.6 | Reagent preparation of 1% acid alcohol..... | 28 |
| 3.2.2.7 | Reagent preparation of 0.3% ammonia water..... | 29 |
| 3.2.3 | Materials for protein expression analysis..... | 29 |
| 3.2.3.1 | Reagent preparation of 1X TBS Tween-20..... | 29 |
| 3.2.3.2 | Reagent preparation of 80% ethanol..... | 29 |
| 3.2.3.3 | Reagent preparation of 95% ethanol..... | 29 |
| 3.2.3.4 | Reagent preparation of 0.3% hydrogen peroxide..... | 30 |
| 3.2.3.5 | Reagent preparation of 1X Citrate buffer (pH 6.0)..... | 30 |
| 3.2.3.6 | Reagent preparation of 1X Tris-EDTA (pH 9.0)..... | 30 |
| 3.2.3.7 | Reagent preparation of Large Volume UltraAb Diluent Plus kit.. | 30 |
| 3.2.3.8 | Reagent preparation of UltraVision ONE Large Volume Detection System HRP Polymer kit (Ready-To-Use)..... | 30 |
| 3.2.3.9 | Reagent preparation of DAB Plus Substrate system..... | 31 |
| 3.2.3.10 | Primary antibodies for immunohistochemistry analysis..... | 31 |
| 3.2.4 | Materials for gene expression analysis..... | 33 |
| 3.2.4.1 | Materials for RNA extraction..... | 33 |
| 3.2.4.2 | Materials for RNA qualification and quantification..... | 33 |
| 3.2.4.3 | Materials for first strand cDNA synthesis..... | 35 |
| 3.2.4.4 | Materials for Taqman gene expression assay..... | 35 |

| | |
|---|----|
| 3.3 Methodology..... | 36 |
| 3.3.1 <i>In vivo</i> mammary carcinoma..... | 36 |
| 3.3.1.1 Animal..... | 36 |
| 3.3.1.2 MNU administration in rat..... | 37 |
| 3.3.1.3 Experimental Design..... | 39 |
| 3.3.1.4 Tumour samples collection..... | 40 |
| 3.3.2 Histological staining..... | 40 |
| 3.3.2.1 Tumour tissue processing..... | 41 |
| 3.3.2.2 Tissue embedding and sectioning..... | 41 |
| 3.3.2.3 Harris Haematoxylin and eosin staining..... | 41 |
| 3.3.2.4 Tumour classification and grading..... | 42 |
| 3.3.3 Immunohistochemical staining..... | 42 |
| 3.3.3.1 Tissue preparation for immnohistochemistry..... | 43 |
| 3.3.3.2 Immunohistochemistry procedure..... | 43 |
| 3.3.3.3 Immunohistochemistry scoring..... | 44 |
| 3.3.4 Gene Expression Study..... | 45 |
| 3.3.4.1 RNA Extraction..... | 45 |
| 3.3.4.2 cDNA synthesis..... | 46 |

| | |
|--|----|
| 3.3.4.3 Primer design and quantitative Real-Time Polymerase Chain Reaction (RT-PCR)..... | 47 |
| 3.3.4.4 Quantitative Real-time analysis..... | 50 |
| 3.3.4.5 PCR efficiency..... | 50 |
| 3.3.5 Statistical analysis..... | 51 |

CHAPTER 4- RESULTS

| | |
|---|----|
| 4.1 MNU induced rat mammary carcinoma..... | 52 |
| 4.1.1 Tumour incidence and latency of MNU induced mammary carcinoma | 52 |
| 4.1.2 Intervention of Rapamycin and/ or PF4..... | 54 |
| 4.2 Histopathological analysis..... | 55 |
| 4.2.1 Characterization of MNU induced mammary tumour in untreated group | 55 |
| 4.2.2 Comparison between control and treatment groups..... | 59 |
| 4.3 Protein expression analysis..... | 61 |
| 4.3.1 ER, PR and PPAR γ expressions in control and treatment groups.... | 61 |
| 4.3.2 Association of ER, PR and PPAR γ expression within treatment group | 64 |
| 4.4 Gene expression analysis..... | 65 |
| 4.4.1 Quantification of RNA and determination of RNA integrity..... | 65 |
| 4.4.2 Quantitative Real-Time PCR analysis..... | 66 |

| | | |
|----------------------------|---|----|
| 4.4.2.1 | Confirmation of primer specificity..... | 66 |
| 4.4.2.2 | Real-time PCR amplification efficiencies and linearity..... | 67 |
| 4.4.3.3 | Relative expression ratio (R) of ER, PR and PPAR γ mRNAs in Rapamycin and/or PF4- treated groups..... | 68 |
| CHAPTER 5- DISCUSSION | | |
| 5.1 | Histological features of mammary carcinoma in MNU-induced rat..... | 71 |
| 5.2 | Influence of Rapamycin on tumour growth, histological features and steroid receptors expression in MNU-induced mammary carcinoma..... | 72 |
| 5.3 | Influence of PF4 on tumour growth, histological features and steroid receptor expressions in MNU induced mammary carcinoma..... | 75 |
| 5.4 | Influence of combination of Rapamycin and PF4 on Steroid Receptor... | 76 |
| CHAPTER 6- CONCLUSION..... | | |
| 6.1 | Summary of current study..... | 78 |
| 6.2 | Limitation of study..... | 79 |
| 6.3 | Recommendation of future research..... | 79 |
| REFERENCES..... | | |
| | | 81 |
| APPENDIX..... | | |
| | | 94 |

LIST OF PRESENTATION

1. **Zaihassni MY**. Wirdatul-Nur, Hilda SS, Damitri TD, Azman Seeni, Hasnan Jaafar. Effect of N-Nitro-N-Methylurea (MNU) on Tumour Incidence and Tumour Number in Rat Breast Cancer Model: A Preliminary Study. 16TH National Conference on Medical and Health Sciences 2011, 22-23 June 2011, Health Campus, USM.
2. **Zaihassni**, Wirdatul-Nur, Damitri TD, Shahidan, Hilda SS, Azman Seeni, Hasnan Jaafar. Effect of Rapamycin and Platelet Factor-4 (PF4) on 1-Methyl-1-Nitrosourea (MNU)-induced Breast cancer. 17TH National Conference on Medical and Health Sciences 2012, 27-28 May 2012, Health Campus, USM.
3. Hilda SS , Zulkifli MM, Fauziah MI, Wirdatul-Nur M.K , **Zaihasni M.Y**, Hasnan J. Cell line development of NMU-induced malignant breast cancer. 17TH National Conference on Medical and Health Sciences 2012, 27-28 May 2012, Health Campus, USM

LIST OF TABLE

| | | Page |
|-------------------|--|------|
| Table 3.1 | List of antibodies and immunohistochemical method used in this study | 32 |
| Table 3. 2 | List of primers and probes sequences used in Real-Time PCR | 49 |
| Table 4. 1 | Percentage of histopathological features of control and treatment groups. | 60 |
| Table 4.2 | ER localization in control and treatments groups. | 61 |
| Table 4.3 | PR localization in control and treatments groups. | 62 |
| Table 4.4 | PPAR γ localization in control and treatments groups. | 62 |
| Table 4.5 | Summary of ER, PR and PPAR γ correlations in treatment groups. | 64 |
| Table 4.6 | Relative mRNA expression level ER,PR and PPAR γ mRNA expression level in experimental groups relative to control group. | 69 |

TABLE OF FIGURES

| | | Page |
|------------|--|------|
| Figure 2.1 | Estimated breast cancer incidence worldwide in 2012 | 5 |
| Figure 2.2 | The percentage of ten most frequent cancer diagnosed among Malaysian in 2007. (Omar and Ibrahim Tamim, 2011) | 8 |
| Figure 2.3 | Percentage of ten most frequent cancer detected in Malaysian female in 2007 (Omar and Ibrahim Tamim, 2011) | 8 |
| Figure 2.4 | The chemical structure of sirolimus. (Yardley, 2013) | 3 |
| Figure 2.5 | The PI3K/Akt/mTOR pathway. Abbreviations: 4E-BPs, 4 eukaryotic binding proteins; EIF4K, eukaryotic initiation factor 4K; mTORC, mammalian target of rapamycin complex; PTEN, phosphatase and tensin homolog; S6K1, ribosomal protein S6 kinase 1; S6, ribosomal protein S6; TSC1, tuberous sclerosis complex1; TSC2, tuberous sclerosis complex 2; PI3K, phosphoinositide 3-kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF-1R, insulin growth factor 1; Akt/PKB, protein kinase B; AMPK, AMP-activated protein kinase; LKB1, liver kinase B1; ILK, integrin-linked kinase (Lane and Leibold, 2006). | 15 |
| Figure 2.6 | Structure of estrogen receptor (ER) and progesterone receptor (PR). ER consists of two isoforms ER α and ER β that are transcribed from two genes. PR also consists of two isoforms PRA and PRB that are transcribed from a single gene using an alternative promoter and translation start site. Abbreviations: DBD, DNA-binding domain; LBD, ligand-binding domain. (Cui <i>et al.</i> , 2005) | 18 |
| Figure 2.7 | Genomic and nongenomic ER pathway in estrogen receptor (ER)-positive tumor cells. (Pietras and Marquez-Garban, 2007) | 19 |
| Figure 2.8 | Schematic diagram of PPAR γ signaling. Abbreviations: PPAR γ : Peroxisome Proliferated Activation gamma; RXR α : Retinoid-X-Receptor alpha; DBD: DNA Binding Domain; RNA: Ribonucleic Acid. (Rumi <i>et al.</i> , 2004) | 22 |
| Figure 3.1 | Flow chart of study | 25 |

| | | |
|------------|---|----|
| Figure 3.2 | Three rats were placed in each cage and fed with pallet and water <i>ad libitum</i> . | 37 |
| Figure 3.3 | Photograph illustrating of MNU administration by intraperitoneal injection. | 38 |
| Figure 3.4 | The mean diameter size of cervical-thoracic mammary lesion was measured by using vernier caliper. | 38 |
| Figure 3.5 | Intralesion treatment injection. | 40 |
| Figure 4.1 | Photograph of mammary carcinomas in rat. One mammary lesion located at the cervical- thoracic region (A) and multiple mammary lesions located at the cervical-thoracic and abdominal inguinal region (B). | 53 |
| Figure 4.2 | Photograph of vascularized mammary tumour. Prominent blood vessel supplies nutrient and oxygen for the tumour growth (arrow) | 53 |
| Figure 4.3 | Photograph measuring of tumour size using vernier caliper. Rapamycin inhibited the progression of MNU induced mammary tumours in rats. Intervention of Rapamycin was done when tumour size was 14.5 ± 0.5 mm (A). After 5 days, the size decreased to 8.5 mm (B). | 54 |
| Figure 4.4 | Photomicrograph of normal mammary gland of female Sprague-Dawley rat. Mammary ducts are surrounded by adipose and fibrous tissue with varied distribution. H&E staining magnification 400x. Epithelial cell (EC) myoepithelial cell (MC). | 56 |
| Figure 4.5 | Photomicrograph of MNU-induced Cribriform Carcinoma. H&E staining magnification 400x. Tumour cell (TC). | 57 |
| Figure 4.6 | Photomicrograph of MNU-induced Papillary Carcinoma. The papillary carcinoma is characterized by displaying numerous papillary projections with thin fibrovascular core. H&E staining magnification 400x. Tumour cell (TC), Fibrovascular Core (FC). | 58 |
| Figure 4.7 | Photomicrograph of MNU-induced IDC-NOS Carcinoma. The carcinoma was of high grade, displayed diffuses infiltration of neoplastic cells, with less tubule formation, highly nuclear pleomorphism and high mitotic rate. H&E staining magnification 400x. Tumour cell (TC), Mitotic Figure (MF), Blood Vessel (BV), Tubule (T). | 59 |

- Figure 4.8 Incidence of MNU-induced breast carcinoma in control and all experimental groups. Based on histological grade, Rapamycin and combination of Rapamycin and PF4 significantly reduced tumour aggressiveness. * denotes significance with p-value <0.05 60
- Figure 4.9 Microphotograph illustrating immunohistochemical expressions of representative markers on tumour specimens. (A) Nuclear positivity of ER in untreated control tissue, (B) overexpression of ER in Rapamycin-treated tissue. (C) PR positivity in untreated control tissue, (D) overexpression of PR in combination of Rapamycin and PF4-treated group. (E) Negative PPAR γ expression in untreated-control tissue, (F) positive cytoplasmic localization of PPAR γ in Rapamycin-treated group. Magnification: 200x 63
- Figure 4.10 Total RNA extracted from rat mammary tumours. RNAs (300ng) were loaded into 1% agarose gel in 1X LB buffer for gel electrophoresis process. High range RNA ladder (Fermentas, USA) (M), RNA 1 (R1), RNA 2 (R2) and RNA 3 (R3) 65
- Figure 4.11 Amplified PCR of ER, PR and PPAR γ target transcripts and ACTB gene with the expected sizes. O'GeneRulerTM Ultra Low Range DNA ladder marker (Fermentas, Canada) (M) and non treatment control (NTC) of ER, PR, PPAR γ and ACTB 66
- Figure 4.12 Amplification plot of β -actin (ACTB), ER, PR , and PPAR γ 67
- Figure 4.13 Summary of the relative expression level of transcripts in experimental groups compared to untreated control group after normalization with β -actin. The data are the $\log_2 R \pm SE$ (relative expression ratio \pm standard error). *** denote significant p-value < 0.001 70

LIST OF ABBREVIATIONS

| | |
|-------------------------------|---|
| g | - gram |
| kg | - kilogram |
| mg | - miligram |
| ml | - mililiter |
| mM | - milimolar |
| M | - molar |
| ng | - nanogram |
| µg | - microgram |
| µl | - microliter |
| µm | - micrometer |
| cDNA | - complementary deoxyribonucleic acid |
| DAB | - diaminobenzidine |
| DAG | - 1, 2-diacylglycerol |
| DCIS | - Ductal carcinoma in situ |
| DEPC | - diethylpyrocarbonate |
| dH ₂ O | - distilled water |
| DMBA | - 7,12-dimethylbenz(a)anthracene |
| EDTA | - ethylenediamine tetraacetic acid disodium |
| ERK | - extracellular signal-regulated protein kinase |
| FFPE | - formalin fixed paraffin embedded |
| H ₂ O ₂ | - Hydrogen peroxide |

| | |
|---------|---|
| H&E | - Hematoxylin and Eosin (stain) |
| HRP | - Horseradish peroxidase |
| IDC-NOS | - Invasive ductal carcinoma-not otherwise specified |
| L | - liter |
| LB | - Lithium Boric acid buffer |
| MAPK | - mitogen-activated protein kinase |
| mRNA | - messenger ribonucleic acid |
| NBF | - Neutral buffered formalin |
| MNU | - 1-methyl-1-nitrosourea |
| PF4 | - Platelet Factor 4 |
| PI3K | - phosphoinositide 3-kinase |
| PPAR | - Peroxisome proliferator-activated receptor |
| qRT-PCR | - quantitative real-time PCR |
| RNA | - ribonucleic acid |
| TBS | - Tris Buffer Saline |
| TDLU | - terminal ductal lobular unit |
| TEB | - terminal end bud |
| VEGF | -Vascular endothelial growth factor |
| ER | - Estrogen Receptor |
| PR | - Progesterone Receptor |
| AI | - Aromatase Inhibitor |
| mTOR | - Mammalian Target of Rapamycin |
| IDP | - Intraductal proliferations |

| | |
|----------|---|
| rhPF4 | - Recombinant Platelet Factor 4 |
| HSPG | - Heparan Sulfateproteoglycans |
| kDa | - Kilo Dalton |
| RXR | - Retinoid-X Receptor |
| r.p.m | - rotation perminute |
| dNTP | - deoxyribonucleotide triphospates |
| REST-MCS | - Relative Expression Software Tool-Multiple Condition Solver |
| rRNA | - ribosomal ribonucleic acid |
| SE | - Standard Error |
| mTORC1 | - Mammalian Target of Rapamycin Complex 1 |
| mTORC2 | - Mammalian Target of Rapamycin Complex 2 |

PERKEMBANGAN KANSER PAYU DARA PADA TIKUS DI BAWAH KESAN
PLATLET FAKTOR-4 (PF4) DAN/ ATAU RAPAMAISIN

ABSTRAK

Kanser payu dara merupakan punca utama kematian dalam kalangan wanita di seluruh dunia. Reseptor steroid seperti Estrogen Receptor (ER) dan Progesteron Receptor (PR) memainkan peranan penting dalam perkembangan kanser payu dara. Dalam kajian ini, ER dan PR dipilih sebagai penanda untuk menentukan kehadiran reseptor steroid kerana perkembangan kanser payu dara bergantung kepada hormon steroid seperti yang telah dilaporkan dalam kebanyakan kajian terdahulu. Selain itu, Peroxisome Proliferator Activation Receptor γ (PPAR γ), salah satu ahli keluarga dalam kumpulan reseptor hormon nukleus juga ditentukan kerana ianya berperanan dalam pembahagian sel tumor. Rapamaisin, sejenis bahan daripada mikrolid bakteria dan Platelet Faktor-4 (PF4), sejenis kemokin mempunyai ciri-ciri antikanser. Oleh itu, ianya menarik untuk mengkaji kesan Rapamaisin dan PF4 dalam menghalang perkembangan kanser payu dara disebabkan oleh kesan hormon. Dalam kajian ini, kanser payu dara diaruh dengan menggunakan 1-Methyl-1-Nitrosourea (MNU) dengan dos 70mg/ kg berat badan terhadap 80 ekor tikus betina strain Sparague Dawley. Pengekspresan gen dan protein untuk ketiga-tiga reseptor ini ditentukan dengan menggunakan teknik imunohistokimia dan Real-Time PCR. Hasilnya, semua tumor payu dara merupakan 100% malignan, mempunyai ciri *invasive ductal carcinoma (IDC)* yang kebanyakannya adalah jenis *cribriform, papillary and Not Otherwise Specified (NOS)*. Perawatan dengan Rapamaisin menunjukkan perencatan perkembangan tumor dan pengurangan keagresifannya. Walaupun pengekspresan ER, PR berlebihan, pengaktifan PPAR γ boleh mengaruh pembahagian sel tumor dan

seterusnya menukar fenotip agresif tumor kepada fenotip kurang agresif. Manakala, perawatan dengan PF4 tidak merencat perkembangan tumor dan juga tidak menunjukkan pengkspresan yang signifikan bagi ER, PR dan PPAR γ . Pengaktifan kawalaturan bagi ketiga-tiganya dalam perawatan kombinasi menyebabkan tumor berjaya direncat dan keagresifan tumor berjaya disekat. Ianya dijangka bahawa Rapamaisin lebih menunjukkan kesan antikanser berbanding PF4. Oleh itu, kajian ini mencadangkan bahawa Rapamaisin bukanlah penggalak atau sinergi dengan PF4. Kesimpulannya, Rapamaisin berpotensi dalam memainkan peranan sebagai antikanser kerana ia menghalang perkembangan tumor dan mengaruh pembezaan sel tumor melalui pengekspresan yang positif bagi reseptor hormon steroid. Kajian yang lebih mendalam diperlukan bagi mengkaji pengawalaturan jenis isoform bagi ER (ER α dan ER β) dan PR (PR-A dan PR-B) bagi meningkatkan strategi rawatan kanser payu dara dengan menggunakan antikanser seperti Rapamaisin.

BREAST CANCER DEVELOPMENT IN RATS UNDER THE INFLUENCE OF PLATELET FACTOR-4 (PF4) AND/ OR RAPAMYCIN

ABSTRACT

Breast cancer is a leading cause of morbidity and mortality among women worldwide. Steroid hormone receptors such as Estrogen Receptor (ER) and Progesterone Receptor (PR) play a critical role in breast cancer growth. In this study, ER and PR were selected as markers for steroid receptor determination due to the strong association between breast cancer development and the influence of steroid hormones as demonstrated in many studies. On the other hands, the Peroxisome Proliferator Activation Receptor γ (PPAR γ), a family of nuclear hormone receptor was also determined as it was a potential effector for tumour cell differentiation. Rapamycin, a drug from bacteria microlide and Platelet Factor-4 (PF4), a platelet-derived chemokine have anticancer properties. Therefore, it will be interesting to analyse the effect of Rapamycin and PF4 in blocking the growth of breast cancer from responding to hormone stimulation. In this study, invasive mammary carcinoma was induced with 70mg/kg body weight 1-Methyl-1-Nitrosourea (MNU) in 80 young female Sprague Dawley rats. The gene and protein expressions of ER, PR and PPAR γ markers were evaluated by using semiquantitative immunohistochemistry analysis and quantitative real-time PCR assay. Findings from the untreated-control group demonstrated that all mammary lesions are 100% malignant, histopathologically characterized with invasive ductal carcinoma (IDC) of three major type ie. cribriform, papillary and Not Otherwise Specified (NOS). Rapamycin treatment showed significant inhibition of mammary tumour progression as well as reduction of tumour aggressiveness. Even though treatment with Rapamycin

significantly overexpressed ER and PR , activation of PPAR γ promotes differentiation of tumour cells which lead to a more differentiated mammary tumour and consequently reversing the aggressive phenotype of the lesion. Meanwhile, treatment with PF4 did not regress tumour growth and consequently showed no significant expression of ER, PR and PPAR γ . Upregulation of all these three markers in combination treatment lead to significant tumour regression and phenotypically decreased aggressiveness. It was predicted that Rapamycin predominantly showed anticancer effect rather than PF4. Thus, present findings suggested that Rapamycin is neither synergistic nor additive with PF4. It was concluded that Rapamycin is a potent anticancer agent for breast cancer because it halt tumour growth and thus promote tumour cells differentiation through a positive expression of hormone receptors analysis. Further study will be needed to analyse the regulation of ER isoforms (ER α and ER β) and PR isoforms (PR-A and PR-B) to improve potential therapeutic strategy in breast cancer treatment through anticancer effects of Rapamycin.

CHAPTER 1

INTRODUCTION

1.1 Background of the study

Increased incidences of cancer have been noted worldwide. According to The International Agency for Research on Cancer (IARC), a total of 14.1 million new cancer cases were reported in 2013 compared to 12.7 million in 2008. Consequently, the number of cancer related death also increased from 7.6 million cases to 8.2 million cases within the five years (Ferlay J. *et al.*, 2013). Moreover, In the United States, the incidence rate of invasive cancer was ranged from 387 to 509 per 100,000 population in 2009 compared to 380 to 511 per 100,000 population in 2010 (Henley *et al.*, 2014). Among the invasive cancers, breast cancer is commonly related to women and the most prevalence cancer among women. It was the second disease commonly diagnose after lung cancer and also known as silent killer to women (522 000 deaths in 2012). Furthermore, according to GLOBOCAN 2012, a new version of IARC's online database, the global breast cancer risk also rises sharply as the frequently diagnosed cancer among women in 140 of 184 countries worldwide (Ferlay *et al.*, 2013).

In Malaysia, The National Cancer Registry 2007 (NCR) also reported breast cancer as the first most common cancer among population regardless of sex. There were 3, 242 female breast cancer cases diagnosed in 2007 among Malaysians with the highest percentage of occurrence (32.1%) followed by other nine malignancies

such as colorectal (10%), cervix uteri (8%), trachea; bronchus; lung (5.4%), corpus uteri (4.1%), leukemia (3.2%), lymphoma (3.2%), thyroid (3.0%) and stomach (2.8%).

Cancer is malignant neoplasm which is critically dependent on the host for nutrition and blood supply. Some neoplasms require endocrine support such as breast cancer. Estrogen and Progesterone are steroid hormones; play a major role in controlling the progression of breast cancer cells. However, both hormones are activated through the binding to their respective receptors namely Estrogen Receptor (ER) and Progesterone Receptor (PR). It was reported that up to 75% of breast cancers express positivity of ER and/ or PR which is marked as prognosis factor breast cancer therapy. Thus, patients with at least 10% ER positive breast cancer cells in primary tumour effectively responded to endocrine therapy and had better survival after relapse (Yamashita *et al.*, 2006). On the other hand, a member of nuclear hormone receptor superfamily, Peroxisome Proliferator Activated Receptor- γ (PPAR γ) also tends to become prognosis factor for cancer therapies. Deficient expression of PPAR γ can be a determinant to breast cancer carcinogenesis (Mueller *et al.*, 1998; Apostoli *et al.*, 2014). As ER expression increases, the inverse relationship between receptor expression and proliferation becomes dysregulated. Increased ER expression is one of the very earliest changes occurring in the tumorigenic process to malignant transformation of breast cancer cells. Therefore, cancer cells progression also depend on several molecular pathways which dysregulated in cancer cells in order to activate the cell proliferations.

Angiogenesis is defined as the formation of a new vascular network out of pre-existing vessels (Folkman, 1995; Papetti and Herman, 2002). It plays a pivotal role in sustaining tumour growth in cancer through the activation of angiogenic and angiostatic

factors such as vascular endothelial growth factor, basic fibroblast growth factor and platelet-derived growth factor (Boudreau and Myers, 2003). On the other hands, other stimuli can also regulate angiogenesis in direct or indirect manners such as soluble growth factors, membrane-bound proteins, cell-matrix and cell-cell interactions (Papetti and Herman, 2002; Otrrock *et al.*, 2007a), hypoxia (Boudreau and Myers, 2003), inflammation and others (Milkiewicz *et al.*, 2006). Nowadays, inhibition of angiogenesis is a kind of strategy for cancer treatment, whereas Platelet factor-4 (PF4) is proven to has anticancer property of angiogenesis inhibition by suppressing endothelial cell proliferation, migration, angiogenesis and metastasis *in vitro* and *in vivo* (Jouan *et al.*, 1999; Struyf *et al.*, 2007; Verpelli *et al.*, 2010).

Moreover, several findings have ruled out that Rapamycin inhibits tumour cell growth by blocking tumour cell proliferation and angiogenesis. It also proven to successfully regress the cancer progression by blocking the cell cycle at S and G1 phase during mitosis and also induced apoptosis in cancer cell (Guba *et al.*, 2002). Rapamycin exerts its activation through a tyrosine/ kinase protein mammalian Target of Rapamycin (mTOR) which is one of the key modulator for cell proliferation (Namba *et al.*, 2006; Sabine *et al.*, 2010).

Nowadays, Tamoxifen and Aromatase Inhibitors become favorable therapies in hormonal positive breast cancer treatments by halting hormonal activities and hormone production for cancer cell progression and survival. It is interesting to discover the anticancer potential of Rapamycin and PF4 toward hormonal activities in breast cancer. In order to determine gene and protein expression of steroid receptors in Rapamycin and/or PF4-treated breast cancer, this study was undergone by using animal model for breast cancer. For *in vivo* experiments, MNU-induced mammary carcinoma in rats is the model of choice. The MNU induced mammary

tumours are comparable to human due to the site of origin, hormone dependant and characterized with malignant and aggressive histological features like human (Russo and Russo, 2000; Thompson and Singh, 2000).

1.2 Objectives of the study

The general objective of the study is to analyse the expression of steroid growth receptors i.e ER, PR and PPAR γ of MNU induced breast cancer under the influences of PF4 and/or Rapamycin in animal model.

1.2.1 Specific objectives

The specific objectives of the study are:

1. To analyse histopathological features of MNU induced tumours treated with Rapamycin and/ or PF4.
2. To analyse protein expression of ER, PR and PPAR γ of treated tumours using immunohistochemistry.
3. To analyse gene expression of ER, PR and PPAR γ of treated tumours using quantitative Real-Time PCR.
4. To correlate expression of ER, PR and PPAR γ with aggressiveness of treated tumours.

CHAPTER 2

LITERATURE REVIEW

2.1 Breast Cancer

2.1.1 The prevalence of breast cancer worldwide

Breast cancer is a common disease in the worldwide. Looking at the world as a whole, the occurrence rate slightly increases every year and commonest among women (Jemal *et al.*, 2010; Chen *et al.*, 2013a; Henley *et al.*, 2014). Figure 2.1 shows the incidence of breast cancer worldwide based on world age-standardized rate per 100, 000 persons in 2012.




Figure 2.1 Estimated breast cancer incidence worldwide in 2012.

(Source: GLOBACON 2012).

According to GLOBACON 2012, breast cancer (1.7 million cases) is the second common cancer diagnosed after lung cancer (1.8 million cases) from year 2008 to 2012 with a sharp increase for incidence number and mortality rate at 20% and 14% respectively (Bray *et al.*, 2013). Furthermore, Henley and co-workers also reported the invasive malignancies among female in the United State is the breast cancer followed by lung, colorectal, and uterine cancer (Henley *et al.*, 2014).

It was surprising that from year 1990 to 2008, the number of females burdened with breast cancer in European countries is high among female aged below than 35 years old. Moreover, they were also detected with high incidence of ductal carcinomas (Leclere *et al.*, 2013). Ductal carcinoma in situ (DCIS) has become a relatively common malignancy detected upon diagnosis. According to data from International Cancer Screening Network (ICSN), based on age-standardized, detection rates of DCIS varied from 0.41 to 1.38 per 1000 women in Europe, United State and Japan. The rate varies across the countries as a result of different DCIS diagnosis and treatment processes (Ponti *et al.*, 2014).

In Asia, for instance, China cancer registry also stated that breast cancer is one of the top ten common cancers leading to death in age-standardize China population with mortality rate 5.13 per 100, 000 and frequently diagnosed among female (incidence rate 42.55 per 100, 000) in year 2009 (Chen *et al.*, 2013a).

2.1.2 Breast cancer risks in Malaysia

In Malaysia, the exact causes for breast cancer risks are still unknown. However, several risk factors increase the chance of getting this disease were

categorized by uncontrollable and controllable factors. Briefly, the uncontrollable factors are family history and age, whereas the controllable factors are breast feeding, food intake, alcohol intake, smoking habits and physical exercises (Baqtayan *et al.*, 2012)

As shown in Figure 2.2, The National Cancer Registry 2007 has reported that breast cancer (18.1%) is the most frequent diagnosed cancer among the Malaysian compared to colorectal (12.3%), trachea, bronchus, lung (10.2%), nasopharynx (5.2%), cervix uteri (4.6%), lymphoma (4.3%), leukemia (4.1%), ovary (3.6%), stomach (3.5%) and liver (3.3%). Moreover, Malaysian females are suffering from breast cancer more than other cancers (Figure 2.3) and it was estimated that one in twenty women in the country developed breast cancer in their lifetime. Among them, Chinese women are commonly diagnosed with this disease followed by Indians and Malay (Baqtayan *et al.*, 2012) as the effect of different culture and lifestyle. Ironically, their overall survival rate was lower than Western, especially Malay women due to delaying for diagnosis and treatment at hospital; after a long period of symptom, presented at the late stage, had larger tumour size and more lymph nodes affected (Ibrahim *et al.*, 2012; Abdullah *et al.*, 2013). Therefore, it is important to promote breast cancer screening in all Malaysian women for early detection and treatment in order to reduce the number of breast cancer fatality and disease burden in Malaysia. Consequently, many breast cancer prevention and control programs are implemented by the government to improve breast health in our country includes encouraging breast self examination in all women, free mammogram screening in government hospital and a RM50 subsidy for every mammogram done in private clinics and hospitals registered with the National Population and Family

Development Board Malaysia (NPFDB) for those who are burdened with high risk of breast cancer (Dahlui *et al.*, 2011).




Figure 2.2 The percentage of ten most frequent cancer diagnosed among Malaysian in 2007. (Omar and Ibrahim Tamim, 2011)




Figure 2.3 Percentage of ten most frequent cancer detected in Malaysian female in 2007 (Omar and Ibrahim Tamim, 2011)

2.2 MNU induced breast cancer animal model

Animal model systems provide invaluable tools in understanding the complexity of multistep carcinogenesis. For decades, the animal model for breast cancer has been used widely in breast cancer prevention and treatment, as its malignancy progression depends on the hormonal status and histopathologically similar to human. Moreover, there are several availability of known initiating agents potentially promotes breast carcinogenesis, such as viral induction, ionizing radiation and chemical carcinogens such as 1-methyl-1-nitrosourea (MNU), 7,12-dimethylbenz[a]anthracene (DMBA), and 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP) (Russo and Russo, 2000; Imaoka *et al.*, 2014).

MNU-induced mammary carcinoma model has been widely used in the investigation of novel breast cancer chemoprevention and therapeutic. Many extensive informations were available, characterizing pathogenesis of tumour growth associated with this compound (Gusterson and Williams, 1981; Thompson and Adlakha, 1991; Thompson and Singh, 2000; Esendagli *et al.*, 2009). MNU induced mammary tumourigenesis in a dose-dependent manner as high MNU dosage increased the tumour multiplicity, shortened the latency period and produced more malignant tumour than benign (Thompson and Adlakha, 1991; Thompson *et al.*, 1992). In addition, the carcinomas induced by MNU were ovarian hormone dependence in carcinogenic initiation and tumour progression (Thompson *et al.*, 1998a).

Furthermore, the injection of sexually immature female rats with MNU results in a rapid induction of premalignant and malignant mammary gland lesions. It was proven that the mammary tumour was palpable post 35 days MNU administration with 50 mg MNU/ kg body weight at 21 days of age (Thompson *et al.*,

1995). The young mammary gland was more susceptible to carcinogenesis. In younger rats, the terminal end buds (TEB) are not well differentiated and frequently mitosis. It is comprised of intermediate cells, myoepithelial cells and have a single lumen with a smooth border. Tumours arise from ductal epithelial cells as in most human breast carcinomas (Thompson and Singh, 2000; Thompson *et al.*, 2000); whereby the early lesions, called intraductal proliferations (IDP) formed after MNU administration (Thompson *et al.*, 1998b). It was the earliest change observed in mammary parenchyma as the dilation of TEB occurs. The epithelial lining thickening up to six layers thick and the cells have a large, round nucleus, prominent nucleolus, and coarse chromatin along the inner leaflet of the nuclear membrane. Recently, in year 2011, Sharma *et al.* had disclosed the cellular differentiation profile of the MNU-induced rat mammary epithelial cells by quantitative protein expression of the luminal and basal myoepithelial populations (Sharma *et al.*, 2011). The results enhanced rat mammary carcinogenesis model in the study of the role of epithelial cell differentiation in breast cancer.

The epithelial derived mammary neoplasm are predominantly characterized with *in situ* ductal carcinoma (DCIS) and invasive carcinoma of papillary, cribriform and comedo type (Russo and Russo, 2000). Neoplastic transformation of mammary epithelial cells in MNU-induced rats is associated with decrease apoptosis in the lesions (Shilkaitis *et al.*, 2000). Thus, histopathological features of tumour is important because those characteristics have implications for the interpretation of experimental mammary carcinoma in animal.

The pathogenetic characteristics of this experimental model of breast cancer are being defined with the use of molecular techniques, such as an identifiable somatic genetic changes GGA-to-GAA transition in codon 12 of the *Ha-ras* gene is

highly prevalent in MNU-induced rat mammary carcinoma (Lu *et al.*, 1998; Imaoka *et al.*, 2014). The mechanism of initiation of genetic mutation by MNU began when MNU generates O-6-methylguanine, which then base-paired with cytosine and thymidine, leading to a G-to-A transition upon subsequent DNA replication. However, Ha-Ras gene mutation by MNU is inversely proportion to the MNU dosages (Lu *et al.*, 1998; Thompson *et al.*, 2000).

2.3 Anticancer properties of Platelet Factor-4 (PF4)

The CXC-chemokines involve in biological activities such as modulation of inflammation, hemostasis and angiogenesis. Chemokines are cytokines which recruit leukocytes to inflammatory sites, acting as growth factor in tumour development and metastasis and influencing angiogenesis. Platelet Factor 4 (PF4) also known as CXC4 chemokine, a potentially chemokine shown to act as anticancer by inhibiting angiogenesis (Maione *et al.*, 1990; Struyf *et al.*, 2007) and promoting apoptosis (Liang *et al.*, 2013; Din *et al.*, 2014).

PF4 is a product of platelet release reaction, a tetrameric molecule with low molecular weight composed of 70 polypeptide residues. The peptide between amino acids 47 and 70 possess heparin-binding lysine-rich site which play an important role in angiogenesis, especially in the four sites of lysine 61, 62, 65 and 66 which are found on a single α -helix on each PF4 monomer. This heparin binding site located at the carboxyl (COOH) terminal end and positively charged. Meanwhile, the other amino (NH₂) terminal is highly acidic and negatively charged (Deuel *et al.*, 1977; Jouan *et al.*, 1999; Bikfalvi, 2004). Majority of the NH₂ terminal contains three amino acid residues (Glutamine -Leucine- Arginine) named as ELR motif (Belperio *et al.*, 2000). The existence of this motif is also a prediction of pathological features

of CXC chemokine where ELR-positive is potent angiogenesis promoter whilst ELR- negative is potent inhibitor of angiogenesis. The ELR+ CXC chemokines including: CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8. Meanwhile, ELR- CXC chemokines are subdivided into two types: angiostatic ELR- CXC chemokines CXCL4, CXCL4L1 and CXCL14 and Interferon-inducible ELR- CXC chemokines CXCL9, CXCL10, and CXCL11 (Strieter *et al.*, 2004; Keeley *et al.*, 2008). The CXCL4L1, a PF4 variant was successfully inhibited angiogenesis in melanoma and lung carcinoma growth and metastasis in vivo (Struyf *et al.*, 2007). The angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 are mediated by CXCR3 (Struyf *et al.*, 2011). In addition, CXCL4's capacity in inhibiting angiogenesis and promoting immune response had become a tool and target for potential intervention in tumor growth and inflammation with more emphasis on molecular pathways and mechanism of action of PF4 (Kasper and Petersen, 2011).

The mechanism of PF4 inhibition of angiogenesis had been tested as single agents in clinical trials (Hawkins, 1995) whereby the concept of antiangiogenesis therapy was proposed in early 1970s (Folkman and Ingber, 1992). They summarized three strategies for antiangiogenesis; inhibition of release of angiogenic molecules from tumour cells, neutralization of released angiogenic molecule and blocking the vascular endothelial cells from responding to angiogenic stimulation. On the other hand, PF4 blocks the binding of vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF2) to cell surface heparan sulfates which both modulated by heparan sulfateproteoglycans (HSPGs) to their respective receptors during angiogenesis. The heparin binding prevents endothelial cell proliferation, migration and differentiation. In addition, heparin reduces the activation and effects

of matrix metalloproteinases, serine proteases, and heparanases in promoting metastasis (Engelberg, 1999).

PF4 also inhibited cancer cells growth by inducing apoptosis in myeloma cells through a negative regulation of signal-transducer-and-activator-of-transcription-3 (STAT3) in vitro and in vivo (Liang *et al.*, 2013). STAT3 is known to regulate proliferation, apoptosis and angiogenesis in multiple myeloma cells through regulating the expression of its target genes including c-Myc, Bcl-XL, Bcl-2, Survivin and VEGF. This was positively correlated with a study by Din *et. al* in 2014 who proved that the treatment of PF4 successfully caused overexpression of pro-apoptotic protein Bax and regression of Survivin protein expression in rat mammary carcinoma (Din *et al.*, 2014).

2.4 Rapamycin inhibits cancer cell growth

Rapamycin (sirolimus) is a substance extracted from bacteria macrolide of *Streptomyces hygroscopicus* found in the soil of Easter Island, Rapa Nui. It was originally used as antifungal, antibacterial and an immunosuppression agent in kidney transplantation. However, recently scientists discovered its anticancer activity, which leads to several test that came into phase II clinical trial as anticancer agent. The chemical structure of Rapamycin (sirolimus) as shown in Figure 2.5.

pseudopodia to noninvasive cuboidal cells that formed cell-to-cell adhesions of renal cancer cells (Luan *et al.*, 2002) and breast cancer cell line proliferation, growth and apoptosis in vitro (Noh *et al.*, 2004; Kasukabe *et al.*, 2005; Chang *et al.*, 2007). Moreover, in vivo treatment with Rapamycin reduced the aggressiveness of invasive renal and bladder cancer cells, inhibited the growth of MCF-7 cells as xenografts and ductal carcinoma in situ malignancy in mouse model (Luan *et al.*, 2002; Kasukabe *et al.*, 2005; Namba *et al.*, 2006).

Mammalian target of rapamycin (mTOR) is a 289-kDa serine/ threonine kinase protein that integrates multiple signals from growth factors and hormones and plays a central role in the control of cell growth, proliferation, and angiogenesis. It was a downstream target of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Activation of PI3K/Akt/mTOR mediates multiple cellular functions to tumour initiation, progression and survival (McAuliffe *et al.*, 2010).

The Rapamycin has affinity to bind to mTOR protein and consequently caused inactivation of mTOR downstream target. Thus, Rapamycin is also recognized as mTOR inhibitor. In preclinical breast cancer models using MCF-7 cells with constitutively active Akt/mTOR that exhibit hormone and chemotherapy resistance, dual inhibition of PI3K and mTOR inhibitors enhanced the efficacy of selective ER modulator tamoxifen in breast cancer (Chen *et al.*, 2013b). The summary of mechanism of mTOR inhibition in cancer cells is shown in Figure 2.5.




Figure 2.5 The PI3K/Akt/mTOR pathway. Abbreviations: 4E-BPs, 4 eukaryotic binding proteins; EIF4K, eukaryotic initiation factor 4K; mTORC, mammalian target of rapamycin complex; PTEN, phosphatase and tensin homolog; S6K1, ribosomal protein S6 kinase 1; S6, ribosomal protein S6; TSC1, tuberous sclerosis complex1; TSC2, tuberous sclerosis complex 2; PI3K, phosphoinositide 3-kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF-1R, insulin growth factor 1; Akt/PKB, protein kinase B; AMPK, AMP-activated protein kinase; LKB1, liver kinase B1; ILK, integrin-linked kinase (Lane and Lebwohl, 2006).

2.5 Regulation of Estrogen Receptor in Breast Cancer

Cell proliferation, differentiation, apoptosis, and cell motility are promoted and regulated by several factors such as growth factors and hormones (Sherbet, 2005). The hormones related cancer such breast cancer shared different mechanism of carcinogenesis by driving cell proliferation, increase the number of cell division and opportunity for random genetic errors. Meanwhile, breast cancer risk is associated with prolonged exposure to female hormones such as estrogen which is either of ovarian or extra-ovarian origin. It was proven *in vivo* that the tumorigenic response is maximal when the carcinogen is administered to young and virgin intact animals in

which the mammary gland is undifferentiated and highly proliferating (Thompson *et al.*, 1995; Thompson *et al.*, 1998a). Increased proliferation could result in turn in accumulation of genetic damage and stimulation of the synthesis of growth factors that act on the mammary epithelial cells via an autocrine or paracrine loop (Russo and Russo, 1998).

Estrogen had clearly been shown to play a critical role in regulation of growth and differentiation of the normal mammary gland and mammary malignancy. Its Estrogenic activity in cells is mediated by high affinity binding protein receptor namely Estrogen Receptor (ER). Estrogen has direct mitogenic effects and promote paracrine mediators of estrogen action in mammary gland upon positivity of ER in mammary epithelial cell. Moreover, it was proven that ER is co-expressed with the proliferation antigen Ki67 in a population of normal primate mammary epithelial cells (Dimitrakakis *et al.*, 2006). ER expression could be a determinant of estrogen action in other tissues such as uterus and ovary. Studies of the ER expression and function in cancer are very important in improving the new strategies of prevention, diagnosis and therapy in estrogen-dependant cancers (Hayashi *et al.*, 2003). Therefore, ER expression is considered as prognosis factor in cancer therapy especially breast cancer.

There are two types of ER which distinctly regulated breast cancer progression. ER α and ER β (as shown in Figure 2. 6) are the products of two separate genes that are differentially expressed in tissues. ER α is 66kD receptor protein located in cytoplasm and nucleus of cells which is responsible for estrogen-induced mitogenic signaling in epithelial cells in breast, uterine and ovarian tissues. Meanwhile, ER β , 36kD protein located in cytoplasm and functionally controls cell proliferation and differentiation. Both ER isoforms are expressed at similarly low

levels in the normal breast, whereas ER α is predominantly expressed at high level rather than ER β in breast cancer cells. Thus, the expression of ER β is downregulated in lesions such as atypical ductal hyperplasia and DCIS compared with that in normal breast epithelium, as it is inversely correlated with proliferation. This is consistent with the suggestion that the ER β negatively modulates the effects of the ER α (Roger P. et al., 2001).




Figure 2.6 Structure of estrogen receptor (ER) and progesterone receptor (PR). ER consists of two isoforms ER α and ER β that are transcribed from two genes. PR also consists of two isoforms PRA and PRB that are transcribed from a single gene using an alternative promoter and translation start site. Abbreviations: DBD, DNA-binding domain; LBD, ligand-binding domain. (Cui *et al.*, 2005).

In breast cancer treatment therapy, ER status has been used clinically almost 40 decades to identify those patients most likely to benefit endocrine therapies through its signaling pathway (Muscat *et al.*, 2013; Renoir *et al.*, 2013; Palmieri *et al.*, 2014). It has been a central to management in breast cancer as a prognosis factor acts as a guide to treatment (Osborne *et al.*, 1980). ERs are activated by two general mechanisms ligand dependent activation (the classic pathway or genomic pathway), in which estrogen binds to the ER and the resulting estrogen-ER unit then interacts directly with DNA to regulate gene transcription; and ligand independent activation

(non classical pathway or nongenomic pathway), in which an ER is activated, in part, after phosphorylation by growth factor receptors or other molecules with serine or tyrosine kinase domains. This pathway plays a central role in breast cancer development including cell survival, proliferation, and angiogenesis (Hasson *et al.*, 2013). Briefly, the summary of genomic and non-genomic ER signaling pathway is shown in Figure 2.7.




Figure 2.7 Genomic and nongenomic ER pathway in estrogen receptor (ER)-positive tumor cells. (Pietras and Marquez-Garban, 2007)

2.6 Regulation of Progesterone receptor in Breast Cancer

Progesterone is a critical regulator of normal female reproductive function, with diverse tissue-specific effects in the human. The effects of progesterone are mediated by its nuclear receptor (PR); a member of a large family of ligand-activated nuclear transcription regulators. The structure PR was described previously in Figure 2.6.

PR is expressed as two isoforms, PRA and PRB. Both are identical in sequence, except that PRA lacks 164 amino acids at the N-terminus, making it the shorter of the two proteins. In human physiology, the majority of PR positive cells express PRA and PRB at equivalent levels (Mote *et al.*, 2002; Mote *et al.*, 2007).

In vivo study demonstrated PR was important in development of alveoli. PR mediated the binding of progesterone then activated the ductal cells. Upon the crosstalk with the stroma, a signal was passed directly to the alveolar precursor cells. Mammary epithelial cells which lack of PR had a failure in side branching (Briskin *et al.*, 1998). The presence of PR in tumour is also an important predictor of tumour aggressiveness and responsiveness to endocrine therapy. Progesterone receptor has provided a mean in hormonal therapy in breast cancer therapeutics. Both ER/PR +ve and ER+ve/ PR- breast cancer sub typing are responsive to hormonal therapy; however the present of PR+ve enhanced the effectiveness of treatment (Bloom *et al.*, 1980; Osborne *et al.*, 1980; Bardou *et al.*, 2003) Thus the status of ER and PR appears as a prognostic index in the patient selection for the therapy.

2.7 Regulation of Peroxisome Proliferator Activation Receptor in Breast Cancer Cells.

The peroxisome proliferator-activated receptors (PPARs) are a group of ligand-activated transcription factors which belong to the nuclear hormone receptor superfamily proteins. PPARs play essential roles in the regulation of carbohydrate, lipid, protein metabolism, cellular differentiation, development, and tumorigenesis.

There are three types of PPARs namely PPAR alpha (PPAR α), PPAR beta/delta (PPAR δ / PPAR β) and PPAR gamma (PPAR γ) (Roberts-Thomson, 2000). Among the three PPARs subunit, PPAR γ plays a critical role in regulating

tumorigenesis. In general, PPAR γ can be found in adipose tissue, colonic epithelia, macrophages, endothelium, small intestine, liver, breast and others. The high expression of PPAR γ and its RXR α ligand showed activation of this heterodimers potentially induce cell death in transitional bladder cancer (Guan *et al.*, 1999). Furthermore, there was an evidence that a cross-talk between ER and PPAR γ by reciprocal interaction between PPAR γ and ER β significantly inhibits the proliferation and migration of thyroid cancer cells (Chu *et al.*, 2014).

In breast cancer, activation of PPAR γ by respective ligand promotes terminal differentiation of the cancer cells (Mueller *et al.*, 1998); caused dramatic morphological and molecular changes to a less malignant state and well differentiated cells. For instance, a pilot study by (Yee *et al.*, 2007) disclosed the activation of short-term rosiglitazone therapy in early-stage breast cancer patients leads to local and systemic effects on PPAR γ signaling in inhibiting tumour growth and progression in human breast cancer. Meanwhile, estrogen biosynthesis in human breast adipose tissues also successfully inhibited by PPAR γ ligands activity, suggesting as possible implication in breast cancer therapy (Rubin *et al.*, 2000). Moreover, upregulation of BRCA1 and decreasing leptin secretion by activation of PPAR γ in mammary stromal adipocytes regressed mammary tumorigenesis *in vivo* (Skelhorne-Gross *et al.*, 2012). PPAR γ ligands also induced apoptosis and antiproliferation in human breast cancer cell lines (Crowe and Chandraratna, 2004; Lea *et al.*, 2004).

PPAR γ activation mechanism involved the Retinoid-X-Receptor (RXR) and PPAR γ Element (PPRE). The heterodimer of PPAR γ and RXR α interacts with co-regulators. Binding of specific PPAR γ ligand leads to coactivator recruitment and corepressor release. Upon the activation, PPAR γ /RXR α heterodimer binds to the

PPRE which is present in the promoters of target genes and activate gene transcription. Figure 2.8 shows the mechanism of PPAR γ signaling.




Figure 2.8 Schematic diagram of PPAR γ signaling. Abbreviations: PPAR γ : Peroxisome Proliferated Activation gamma; RXR α : Retinoid-X-Receptor alpha; DBD: DNA Binding Domain; RNA: Ribonucleic Acid. (Rumi *et al.*, 2004).

2.8 Histological grades in breast cancer

The purpose of breast cancer classification is to select the best treatment. Breast cancer can be classified based on tumour grade, tumour stage and histological type, receptor status and DNA testing of certain genes.

Grading focuses on the appearance of the breast cancer cells compared to the appearance of normal breast tissue. Cancerous cells are not well differentiated compared the normal cells which take on specific shapes and forms that reflect their function as part of that organ. In cancer, the breast cells become disorganized, cell division becomes uncontrolled and cell nuclei become less uniform. Poorly differentiated cancers have a worse prognosis. The Nottingham also called Elston-Ellis modification of the Scarff-Bloom-Richardson grading system is a grading system currently adopted by World Health Organisation (WHO) (Genestie *et al.*, 1998). This system grades breast carcinomas based on three parameters such as

tubule formation (how much of the tumour tissue has normal breast milk duct structures), nuclear pleomorphism (an evaluation of the size and shape of the nucleus in the tumor cells) and mitotic count (how many dividing cells are present, which is a measure of how fast the tumor cells are growing and dividing) respectively. These features were given 1 to 3 points each which is then added together to give an overall final score of 3 to 9. Tumour grade 3-5 represent well-differentiated cells have best prognosis compared grade 6-7 and 8-9 which represent moderate differentiated and poorly differentiated respectively. Therefore, lower-grade tumors, with a more favorable prognosis, can be treated less aggressively, and have a better survival rate (Bloom and Richardson, 1957; Elston and Ellis, 1991).

CHAPTER 3

MATERIALS AND METHODS

3.1 Study design

This in vivo study involving induction of mammary tumourigenesis in rat by a carcinogen, followed by histological features classification and determination of the effectiveness of anticancer agents through the steroid receptor analysis.

Throughout this study, 1-Methyl-1-Nitrosourea (MNU) was intervened into the female Sparague Dawley rats at the dose of 70mg/kg body weight to promote mammary tumour formation (Jaafar *et al.*, 2009). The tumors were divided into control and treatment groups. Treatment interventions of Rapamycin, Platelet-Factor-4 (PF4) and combination of Rapamycin and PF4 were done when tumour diameter size reached 14.5 ± 0.5 mm. Tumours regression was observed after 5 days of treatment interventions. Both anticancer agents were chosen based on their ability to inhibit cancer progression through anticancer properties towards cancer cells.

All tumour tissues were subjected to histopathological analysis and steroid receptor analysis. The expressions of Estrogen Receptor, Progesterone Receptor and Peroxisome Proliferator Activation Receptor- γ (PPAR- γ) were determined by semiquantitative protein expression of Immunohistochemistry and quantitative gene expression of Real-Time Polymerase Chain Reaction (RT-PCR) assays. Statistical inferences were then performed to justify the results. The study design was summarized as shown in Figure 3.1.